Is Sermorelin Legal in Wisconsin?

HealthRX.com

No Wisconsin rule names sermorelin, and US supply is compounded

Print or save as PDF

See the public record for Sermorelin

  • FDA-approved sermorelin today / None; both Geref applications were withdrawn in 2009 [1]
  • Geref's approved uses / Growth hormone deficiency in children, and a pituitary growth hormone test [1]
  • Why it was withdrawn / The maker discontinued it in 2008 and asked FDA to withdraw; in 2013 FDA found it was not pulled for safety or effectiveness [1]
  • What is sold now / Compounded sermorelin, which FDA does not review for safety, effectiveness or quality [2]
  • FDA safety-risk bulk list / Sermorelin is not on it [3]
  • Sport / Named on WADA's Prohibited List, prohibited at all times [10][11]

What sermorelin's FDA record shows

Sermorelin is a 29-amino-acid analogue of human growth hormone-releasing hormone; it prompts the pituitary to release the body's own growth hormone and is not growth hormone itself [4].

Two Geref applications were approved: NDA 019863, a 0.05 mg ampule for testing the pituitary's ability to secrete growth hormone (December 28, 1990), and NDA 020443, 0.5 mg and 1 mg vials for treating idiopathic growth hormone deficiency in children with growth failure (September 26, 1997). Neither covered adults, anti-aging, weight loss or athletic performance [1].

The manufacturer discontinued Geref in 2008 and asked FDA to withdraw the applications; FDA withdrew both approvals effective June 18, 2009 [1]. In March 2013 FDA determined Geref had not been withdrawn from sale for reasons of safety or effectiveness, and Drugs@FDA lists both products as discontinued. These are the only sermorelin applications in Drugs@FDA [1][5].

What is sold today

With Geref gone, sermorelin products in the US are compounded, and compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they reach patients [2].

Where sermorelin sits on FDA's compounding lists

  • It is absent from FDA's list of bulk substances that may present significant safety risks when compounded (content dated April 22, 2026) [3].
  • On FDA's list of nominated bulk substances for outsourcing facilities, sermorelin acetate is in category 1, under evaluation (list updated March 21, 2025) [7].
  • It appears in no category on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) and is not among the six peptides in HHS's October 2026 draft enforcement-discretion policy [8][9].

Wisconsin

We found no Wisconsin statute or board rule that names sermorelin. The federal records show that no sermorelin product is FDA-approved today and that products sold in the US are compounded and not reviewed by FDA before marketing [1][2].

Questions worth asking

Choose the questions you want to keep

Sport

WADA's 2026 Prohibited List names sermorelin in S2.2.4, growth hormone releasing factors (GHRH and its analogues); it is prohibited at all times, in and out of competition, and the 2027 List names it as well [10][11].

Is sermorelin legal in Wisconsin?
We found no Wisconsin statute or board rule that names sermorelin. Federally, no sermorelin product is FDA-approved and what is sold in the US is compounded, which FDA does not review for safety, effectiveness or quality [1][2].
Is sermorelin FDA-approved?
Not today. Geref was approved in 1990 for a pituitary growth hormone test and in 1997 for growth hormone deficiency in children, and both approvals were withdrawn effective June 18, 2009 [1].
Does WADA prohibit sermorelin?
Yes. WADA's 2026 Prohibited List names sermorelin in S2.2.4 and prohibits it at all times, in and out of competition [10][11].
Show all 11 referencesHide references
  1. Federal Register :: Request Access.
  2. Official web page.
  3. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  4. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
  5. U.S. Food and Drug Administration.
  6. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
  7. U.S. Food and Drug Administration.
  8. U.S. Food and Drug Administration.
  9. Official web page.
  10. World Anti-Doping Agency.
  11. World Anti-Doping Agency.
Sermorelin legal Wisconsin: evidence summary chart
Image: HealthRX.com. Full sermorelin legal Wisconsin guide and sources at healthrx.com/peptide-legal-sermorelin.